Shopping Cart
- Remove All
Your shopping cart is currently empty
EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner. EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $39 | In Stock | |
| 5 mg | $80 | In Stock | |
| 10 mg | $139 | In Stock | |
| 25 mg | $216 | In Stock | |
| 50 mg | $278 | In Stock | |
| 100 mg | $422 | In Stock | |
| 500 mg | $957 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $64 | In Stock |
| Description | EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner. EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase). |
| Molecular Weight | 368.34 |
| Formula | C19H14F2N4O2 |
| Cas No. | 1808714-73-9 |
| Smiles | Fc1ccc(NC(=O)c2cnn(c2)-c2ccccc2F)cc1NC(=O)C=C |
| Relative Density. | 1.32 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 4.63 mg/mL (12.57 mM), Sonication is recommended. Ethanol: 1.10 mg/mL (2.99 mM), Sonication and heating to 60℃ are recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.